Hims & Hers insider uses 10b5-1 plan to sell 11,595 shares
Rhea-AI Filing Summary
Insider transactions on 10/03/2025: the Chief Financial Officer, Oluyemi Okupe, adopted a Rule 10b5-1 plan and executed option exercises and open-market sales. The reporting shows 11,595 shares sold at an average weighted price of $57.7173 (range $57.41–$58.09), and two option exercises: 7,787 options at an exercise price of $5.01 and 3,808 options at $11.53. Post-transaction holdings include reported direct ownership entries for Class A common stock and optioned shares underlying 182,165 and 59,976 share tallies respectively as disclosed. The Form states vesting schedules for the options and notes sales were made under the 10b5-1 plan.
Positive
- Use of a Rule 10b5-1 trading plan provides preclearance and reduces insider-trade timing risk
- Options exercised at low strike prices ($5.01 and $11.53), converting potential compensation into shares
- Disclosed vesting schedules clarify when remaining option-based dilution may occur
Negative
- Open-market sale of 11,595 shares may modestly increase available float at recent prices
- Average weighted sale price reported indicates significant disposal at ~$57.72, reducing the reporting person’s direct stake
Insights
TL;DR: CFO used a prearranged Rule 10b5-1 plan to exercise options and sell shares, realizing liquidity while maintaining vested holdings.
The filings show the CFO exercised 7,787 options at $5.01 and 3,808 options at $11.53, then sold 11,595 shares at an average of $57.7173. Using a Rule 10b5-1 plan provides an affirmative defense under trading-window rules and indicates these trades were preplanned.
Key dependencies include the disclosed vesting schedules—one grant vests over four years with monthly installments beginning 04/01/2023 and the other according to a January 24, 2022 vesting commencement—so future option dilution and remaining insider liquidity depend on continued vesting and any further planned sales under the 10b5-1 arrangement.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 7,787 | $0.00 | -- |
| Exercise | Stock Option (right to buy) | 3,808 | $0.00 | -- |
| Exercise | Class A Common Stock | 7,787 | $5.01 | $39K |
| Exercise | Class A Common Stock | 3,808 | $11.53 | $44K |
| Sale | Class A Common Stock | 11,595 | $57.7173 | $669K |
| holding | Class A Common Stock | -- | -- | -- |
Footnotes (1)
- The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025 by the Reporting Person. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $57.41 - $58.09. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. 25% of the options will vest on the twelve (12) month anniversary of the Vesting Commencement Date of January 24, 2022. The balance of the shares shall vest in a series of thirty-six (36) successive equal monthly installments measured from the twelve (12) month anniversary of the Vesting Commencement Date, subject to optionholder's continuous Service (as defined in the Plan) as of each such vesting date. The options are subject to a service-based vesting requirement, which shall be satisfied over a 4-year period, with 1/48th of the options vesting monthly, beginning on April 1, 2023.
